(Q36150356)

12 August 2017

1 reference

title

Molecular markers that predict response to colon cancer therapy (English)

1 reference

12 August 2017

1 reference

Farid E Ahmed

1

1 reference

12 August 2017

1 May 2005

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

353-375

1 reference

12 August 2017

3

1 reference

Customizing chemotherapy for colon cancer: the potential of gene expression profiling.

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Adjuvant therapy for colon cancer: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Two steps forward in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Surrogate markers in antiangiogenesis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Use of isogenic human cancer cells for high-throughput screening and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

A gene expression database for the molecular pharmacology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

The influence of tumor size and environment on gene expression in commonly used human tumor lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Molecular markers predictive of response to chemotherapy in gastrointestinal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

A Role for P-Glycoprotein in Environmental Toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Markers of drug resistance in relapsing colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Fluoropyrimidine resistance in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Predictive and prognostic markers in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Biomarker discovery and validation: technologies and integrative approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Cancer Therapy: New Targets for Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Farnesyl transferase inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Pharmacological background of EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Cetuximab: in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Antiangiogenic therapy at a crossroads: clinical trial results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Neuropilin is a mediator of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Tumor endothelial markers: new targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

TP53 mutation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Identification of four single nucleotide polymorphisms in DNA repair genes: XPA and XPB (ERCC3) in Polish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

From bench to clinic with apoptosis-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Expression profile analysis of colon cancer cells in response to sulindac or aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Profile of gene expression regulated by induced p53: connection to the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

The contributions of cyclooxygenase-2 to tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Microarray analysis in the clinical management of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Development of novel diagnostic and prognostic molecular markers for sporadic colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.3.353

21 January 2018

Identifiers

DOI

10.1586/14737159.5.3.353

1 reference

12 August 2017

1 reference

PubMed ID

15934813